EX-99.1
2
exh99-1_13035.txt
PRESS RELEASE DATED NOVEMBER 2, 2004

                                                                    EXHIBIT 99.1
                                                                    ------------


[LOGO]
ABLE
LABORATORIES, INC.


COMPANY CONTACTS:                                        INVESTOR CONTACT:
Jay Wadekar, Chairman & CEO                              Investor Relations
Robert Weinstein, Vice President & CFO                   (908) 754-2253 ext. 664
(609) 495-2800                                           Email: IR@ablelabs.com

Able Laboratories Reports Third Quarter 2004 Results

Able Achieves Record Sales, Operating Income and Earnings Per Share

----------
Net Sales Increase 31% to $27.3 Million from $20.9 Million for Third Quarter of
2003
----------
Operating Income Increases 73% to $7.3 Million from $4.2 Million for Q3 of 2003
----------
R&D Expenses of $4.0 Million, an Increase of 32% versus Third Quarter 2003
----------
Diluted Earnings Per Share Increases 77% to $0.23 from $0.13 for Q3 of 2003
----------

CRANBURY, NJ, NOVEMBER 2, 2004 - ABLE LABORATORIES, INC. (NASDAQ NMS: ABRX)
today announced financial results for the three months ended September 30, 2004.

For the third quarter of 2004, the Company reported net sales of $27.3 million,
a 30.8% increase from net sales of $20.9 million in the third quarter of 2003,
primarily due to the Company's expanded product family. The Company also
reported operating income of $7.3 million for the third quarter of 2004, a 73.3%
increase as compared to operating income of $4.2 million for the third quarter
of 2003. This included an increase in Research & Development (R&D) expenses of
$1.0 million, or 31.7%, for the third quarter of 2004 versus the third quarter
of 2003. Diluted earnings per share (EPS) increased to $0.23 for the third
quarter 2004 as compared to diluted EPS of $0.13 for the third quarter of 2003.

Gross profit was $14.9 million for the quarter, an increase of 49.3%, compared
to $10.0 million for the third quarter of 2003. As a percent of net sales, the
Company's gross margin was 54.6%, compared to 47.8% for the third quarter of
2003. Gross margin increased as a percentage of net sales for the quarter
primarily as a result of selling newly-approved products at higher gross
margins. This increase is partially offset by expenses, included in cost of
goods sold, relating to the Company's continuing build-out of the new Cranbury,
New Jersey manufacturing facility.


R&D expenses increased substantially, as noted above. The increase results from
additional research and development conducted to further develop the Company's
product pipeline and costs associated with development partnering arrangements.
R&D expenses accounted for 14.8% of net sales for the third quarter of 2004
versus 14.7% of net sales for the third quarter of 2003. The Company received 10
Abbreviated New Drug Application ("ANDA") approvals during the third quarter.
The Company currently has five ANDAs pending approval by the U.S. Food and Drug
Administration ("FDA") addressing a total market size of approximately $300
million. In addition, the Company has over 25 projects currently under
development addressing a total market size of over $3 billion.

Selling, general and administrative (SG&A) expenses increased to $3.6 million
for the third quarter of 2004, compared to $2.7 million for the third quarter of
2003. SG&A expenses accounted for 13.0% of net sales for the quarter compared
with 12.9% of net sales for the third quarter of 2003. The increase was
primarily attributable to increased administrative, selling and marketing
expenses to support the Company's growth.

Operating income for the third quarter of 2004 was $7.3 million, or 26.7% of net
sales, versus $4.2 million, or 20.2% of net sales, for the third quarter of
2003. This increase is attributable to increased sales and gross margins
partially offset by an increase in R&D and SG&A expenditures. Net income
applicable to common stockholders for the quarter was $4.4 million versus $2.5
million for the third quarter of 2003. Fully diluted earnings per share for the
quarter increased 77.0% to $0.23 versus $0.13 for the third quarter of 2003.

Jay Wadekar, Able's Chief Executive Officer, commented: "We had a very good
quarter in which we achieved record results. We are pleased with Able's progress
during the quarter as we received several ANDA approvals and launched new
products as a result. We continue investing in our future by building the
Company's R&D pipeline.

"To-date, we have moved approximately one-half of our staff into the Cranbury
facility. In addition, during the third quarter, we installed a new Oracle
Enterprise Resource Planning system. The Oracle system will provide us with
increased capabilities and assist the Company in handling anticipated growth
while also better enabling management to maintain stringent controls over the
business.

"We anticipate additional product approvals over the next few months in addition
to the 16 approvals received to date in 2004. We currently have five ANDAs on
file with the FDA and anticipate filing between 15 and 20 additional ANDAs
during the remainder of the year and through the first half of 2005. These
products represent a total market size of approximately $1.5 to $2.0 billion. Of
these products to be filed, five to seven could be first to market based on
exclusive API sourcing. Finally, we plan to continue our commitment to R&D by
increasing the number of new products entering development, both by utilizing
our expanded internal capabilities and through collaboration agreements with
others."

THIRD QUARTER 2004 CORPORATE HIGHLIGHTS

     o    The Company received FDA approval for its ANDA for promethazine
          hydrochloride tablets, USP 12.5mg, 25mg and 50mg. Able was the first
          company to receive an ANDA approval for, and to ship 12.5mg, the
          generic equivalent of Phenergan(R) Tablets, 12.5mg of Wyeth Ayerst
          Laboratories;

                                       2


     o    The Company received FDA approval for its three ANDAs for hydroxyzine
          hydrochloride tablets, USP 10mg, 25mg and 50mg, the generic equivalent
          to hydroxyzine hydrochloride tablets, USP 10mg, 25mg and 50mg of
          Pliva, Inc. (formerly Sidmak Laboratories, Inc.);

     o    The Company received FDA approval for its four ANDAs for bethanechol
          chloride tablets, USP 5mg, 10mg, 25mg and 50mg the generic equivalent
          to Urecholine(R) Tablets, 5mg, 10mg, 25mg and 50mg of Odyssey
          Pharmaceuticals, Inc.;

     o    The Company received FDA approval for its ANDA for atenolol tablets,
          USP 25mg, 50mg and 100mg, the generic equivalent to Tenormin(R)
          Tablets, USP 25mg, 50mg and 100mg of Astra Zeneca Pharmaceuticals LP;

     o    The Company received FDA approval for its ANDA for dextroamphetamine
          sulfate ER capsules, 5mg, 10mg and 15mg, the generic equivalent to
          Dexedrine(R) Spansule(R) sustained-release capsules, 5mg, 10mg and
          15mg of Glaxo SmithKline;

     o    The Company appointed Joan Janulis Vice President, Regulatory Affairs;

     o    The Company appointed Janet E. Penner Vice President, Sales &
          Marketing and Laura Borda-Short, Dennis Hicks and Melanie Cameron as
          vice presidents in the department.

     o    The Company appointed Lisa Graver as Senior Patent Counsel.

CONFERENCE CALL INFORMATION


Able Laboratories has scheduled a conference call and web cast regarding this
announcement to be held tomorrow, Wednesday, November 3, beginning at 10:00 a.m.
Eastern Time (7:00 a.m. Pacific Time). To participate in the live call via
telephone, please call (877) 464-5947 or (706) 679-0842 internationally. A
telephone replay will be available for 48 hours following the call by dialing
(800) 642-1687 or (706) 645-9291 internationally and entering reservation number
1823205.

Individuals interested in listening to the conference call via the Internet may
do so by visiting our web site www.ablelabs.com. A replay will be available on
the web site for 90 days.

Able Laboratories is a developer and manufacturer of generic pharmaceuticals.
Further information on Able may be found on the Company's web site,
www.ablelabs.com.

EXCEPT FOR HISTORICAL FACTS, THE STATEMENTS IN THIS NEWS RELEASE, AS WELL AS
ORAL STATEMENTS OR OTHER WRITTEN STATEMENTS MADE OR TO BE MADE BY ABLE
LABORATORIES, INC., ARE FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF THE
PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 AND INVOLVE RISKS AND
UNCERTAINTIES. FOR EXAMPLE, STATEMENTS ABOUT THE COMPANY'S OPERATIONS, ITS
ABILITY TO FORMULATE AND BRING TO MARKET ITS DRUG PRODUCTS UNDER DEVELOPMENT,
ITS ABILITY TO INCREASE SALES AND PROFITS AND MANAGE ITS GROWTH, THE EXPECTED
EFFECTS OF THE COMPANY'S EXPANSION OF ITS PRODUCTION FACILITIES, THE CURRENT OR
EXPECTED MARKET SIZE FOR THE COMPANY'S PRODUCTS, THE ADEQUACY OF THE COMPANY'S
MANUFACTURING CAPACITY, THE AVAILABILITY OF SUFFICIENT CAPITAL, THE SUCCESS OF
CURRENT OR FUTURE PRODUCT OFFERINGS, RESEARCH AND DEVELOPMENT EFFORTS AND THE
COMPANY'S ABILITY TO FILE FOR AND OBTAIN U.S. FOOD AND DRUG ADMINISTRATION
APPROVALS FOR FUTURE PRODUCTS, ARE FORWARD-LOOKING STATEMENTS. FORWARD-LOOKING
STATEMENTS ARE MERELY THE COMPANY'S CURRENT PREDICTIONS OF FUTURE EVENTS. THE
STATEMENTS ARE INHERENTLY UNCERTAIN, AND ACTUAL RESULTS COULD DIFFER

                                       3


MATERIALLY FROM THE STATEMENTS MADE HEREIN. THERE IS NO ASSURANCE THAT THE
COMPANY WILL CONTINUE TO ACHIEVE THE SALES LEVELS NECESSARY TO MAKE ITS
OPERATIONS PROFITABLE OR THAT ITS ANDA FILINGS AND APPROVALS WILL BE COMPLETED
AND OBTAINED AS ANTICIPATED. FOR A DESCRIPTION OF ADDITIONAL RISKS, AND
UNCERTAINTIES, PLEASE REFER TO THE COMPANY'S FILINGS WITH THE SECURITIES AND
EXCHANGE COMMISSION, INCLUDING ITS QUARTERLY REPORT ON FORM 10-Q FOR THE QUARTER
ENDED JUNE 30, 2004 AND ITS ANNUAL REPORT ON FORM 10-K FOR THE YEAR ENDED
DECEMBER 31, 2003. THE COMPANY ASSUMES NO OBLIGATION TO UPDATE ITS
FORWARD-LOOKING STATEMENTS TO REFLECT NEW INFORMATION AND DEVELOPMENTS.

                           PLEASE SEE ATTACHED TABLES



--------------------------------------------------------------------------------





































                                       4


                             ABLE LABORATORIES, INC.
                         CONDENSED STATEMENTS OF INCOME
                                   (Unaudited)

Three Months Ended Nine Months Ended ------------------------------ ------------------------------ September 30, September 30, September 30, September 30, 2004 2003 2004 2003 ------------ ------------ ------------ ------------ Sales, net $ 27,299,945 $ 20,864,912 $ 71,757,663 $ 54,808,673 Cost of sales 12,404,339 10,886,705 36,515,219 29,281,638 ------------ ------------ ------------ ------------ Gross profit 14,895,606 9,978,207 35,242,444 25,527,035 ------------ ------------ ------------ ------------ Operating expenses: Selling, general and administrative 3,555,674 2,698,980 10,183,850 7,387,648 Research and development 4,041,479 3,068,403 11,081,415 7,471,098 ------------ ------------ ------------ ------------ Total operating expenses 7,597,153 5,767,383 21,265,265 14,858,746 ------------ ------------ ------------ ------------ Operating income 7,298,453 4,210,824 13,977,179 10,668,289 ------------ ------------ ------------ ------------ Other income (expense): Interest and financing expense (42,141) (68,389) (150,726) (489,471) Loss on early retirement of debt -- -- (118,440) (241,999) Miscellaneous income (expense), net (56,175) 97,007 45,516 138,519 ------------ ------------ ------------ ------------ Other income (expense), net (98,316) 28,618 (223,650) (592,951) ------------ ------------ ------------ ------------ Income before income taxes 7,200,137 4,239,442 13,753,529 10,075,338 Provision for income taxes 2,764,000 1,693,200 5,279,000 4,018,100 ------------ ------------ ------------ ------------ Net income 4,436,137 2,546,242 8,474,529 6,057,238 Dividends on preferred stock 16,521 54,400 77,930 232,469 ------------ ------------ ------------ ------------ Net income applicable to common stockholders $ 4,419,616 $ 2,491,842 $ 8,396,599 $ 5,824,769 ============ ============ ============ ============ Net income per share: Basic $ 0.25 $ 0.16 $ 0.49 $ 0.41 ============ ============ ============ ============ Diluted $ 0.23 $ 0.13 $ 0.44 $ 0.34 ============ ============ ============ ============ Weighted average shares outstanding: Basic 17,623,007 15,964,903 17,206,420 14,093,029 ============ ============ ============ ============ Diluted 19,497,309 19,446,592 19,391,772 18,070,456 ============ ============ ============ ============
5 ABLE LABORATORIES, INC. CONDENSED BALANCE SHEETS (Unaudited)
ASSETS September 30, December 31, 2004 2003 ------------- ------------- Current assets: Cash and cash equivalents $ 9,582,332 $ 20,065,248 Accounts receivable, net of allowances of $29,814,286 and 24,007,583 13,926,818 8,626,023 Inventory 21,781,548 16,602,608 Deferred income tax asset 4,760,000 4,760,000 Prepaid expenses and other current assets 2,012,340 1,644,068 ------------- ------------- Total current assets 52,063,038 51,697,947 ------------- ------------- Property and equipment, net 35,316,059 18,953,744 ------------- ------------- Other assets: Debt financing costs, net of accumulated amortization -- 91,708 Cash deposits with bond trustee -- 525,907 Deferred income tax asset 7,338,000 9,709,000 Goodwill 3,922,655 3,904,094 Deposits and other assets 694,224 481,755 ------------- ------------- Total other assets 11,954,879 14,712,464 ------------- ------------- $ 99,333,976 $ 85,364,155 ============= ============= LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Notes payable and current portion of long-term debt $ -- $ 239,038 Accounts payable 5,064,874 3,293,168 Accrued expenses 2,321,406 1,114,976 ------------- ------------- Total current liabilities 7,386,280 4,647,182 Long-term debt, less current portion 3,000,000 3,935,000 ------------- ------------- Total liabilities 10,386,280 8,582,182 ------------- ------------- Stockholders' equity: Preferred stock, $.01 par value, 10,000,000 shares authorized, 5,750 and 17,025 shares of Series Q outstanding (liquidation value $575,000 and $1,702,500) 58 171 Common stock, $.01 par value, 25,000,000 shares authorized, 17,918,234 and 16,761,216 shares issued and outstanding 179,182 167,611 Additional paid-in capital 119,673,513 116,060,210 Accumulated deficit (30,821,412) (39,295,941) Unearned stock-based compensation (83,645) (150,078) ------------- ------------- Total stockholders' equity 88,947,696 76,781,973 ------------- ------------- $ 99,333,976 $ 85,364,155 ============= =============
6

The following information was filed by Able Laboratories Inc on Wednesday, November 3, 2004 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Able Laboratories Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Able Laboratories Inc.

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account